CPC A61K 31/542 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 31/498 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/186 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01)] | 14 Claims |
1. A method of treating elevated intraocular pressure (IOP) in a mammalian eye comprising administering an effective amount of a pharmaceutically acceptable and ophthalmologically suitable composition to the eye no more than twice per 24-hour period, the composition comprising:
(a) a pharmaceutically acceptable and ophthalmologically suitable brinzolamide compound in an amount of about 1 wt. %-about 10 wt. % of the composition; and
(b) a pharmaceutically acceptable and ophthalmologically suitable brimonidine compound in an amount of about 0.02 wt. %-about 0.5 wt. % of the composition, and
(c) benzalkonium chloride in an amount of 0.007 wt. %-about 0.02 wt. % of the composition, and
(d) a pharmaceutically acceptable and ophthalmologically suitable borate-polyol complex in an amount of about 0.5 wt. %-about 6 wt. % of the composition wherein the borate-polyol complex comprises two or more polyol compounds, and wherein the ratio of the benzalkonium chloride to the boric acid is between about 1:14 and about 1:43,
wherein the composition comprises less than 1% non-ionic surfactant, and further wherein performing the method results in an effect that (1) is bioequivalent to or (2) results in a greater bioavailability of the brinzolamide compound, the brimonidine compound, or both, than the administration of a reference product comprising the same amount of a brinzolamide compound and the same amount of a brimonidine compound that is administered three times per 24-hour period; and wherein the composition is in the form of an ophthalmic suspension.
|